Overview
AMR is recognised as a global threat to public health and economic prosperity. With predicted losses of USD $100 trillion in global productivity by 2050, effective AMR mitigation strategies would offer substantial economic benefits while protecting human, animal and environmental health.
The MSCI Sustainability Institute, IAAMR and FAIRR have co-developed an Investor’s Guide to AMR, offering crucial insights into why AMR is a systemic risk. This guide sheds light on the far-reaching impact of AMR on key sectors such as healthcare, pharmaceuticals and animal agriculture, and estimates the percentage of assets impacted by region.
Addressing AMR will require both the development of novel antimicrobials and solutions as well as robust stewardship of existing antimicrobials. The guide provides a comprehensive overview of the current research and development pipeline for novel antimicrobials and highlights how investors could capitalise on opportunities for strategic investments to drive positive change.
Investors can also take action by engaging with companies to improve disclosure and stewardship practises. This guide will equip investors with key questions to consider when adopting an "AMR lens" and provides four insightful case studies from active investors.
Key Highlights
The investor guide aims to:
Provide an overview of the current state of AMR
Outline the systemic risk to investors and key investment considerations
Provide an analysis of potential AMR impacts, risks and opportunities by sub-industry
Assess the impact of AMR on the economy, health, livestock and the environment
Summarise the current research and funding landscapes for novel antimicrobials
Outline the economic case for investment in AMR solutions
Provide case studies from investors demonstrating how they are taking action on AMR
